Group 1 - The company announced the approval of multiple proposals during the first meeting of the 11th Board of Directors in 2026, including the construction of the second phase of the oral liquid project by its wholly-owned subsidiary, Yunnan Baiyao Group Wenshan Qihua Co., Ltd., with a total investment budget of 137.36 million yuan [1] - The company approved the organizational structure plan for 2026 and appointed Dong Ming as CEO, Qian Yinghui as Board Secretary, and Li Mengjue as Securities Affairs Representative, with a three-year term [1] - The company aims to accelerate the establishment of a modern R&D system and capabilities, integrating traditional Chinese medicine with modern technology, by appointing Zhu Zhaoyun as the Strategic Scientist for Traditional Chinese Medicine and Zhang Ning as the Chief Scientist [1] Group 2 - Li Jin retired and will no longer serve as a senior management personnel of the company [1] - Zhu Zhaoyun is an academician of the Chinese Academy of Engineering and has held positions such as Director of Yunnan Provincial Institute of Drug Research and R&D Director of Yunnan Baiyao Group [1] - Zhang Ning is a professor at Peking University and has previously served as Deputy Director of the Medical Department at Peking University and Vice President of Tianjin Medical University [1]

Core Viewpoint - Yunnan Baiyao announced the appointment of Zhu Zhaoyun as the Traditional Chinese Medicine Strategic Scientist and Zhang Ning as the Chief Scientist to enhance its modern R&D system and capabilities, integrating traditional Chinese medicine with modern technology [1] Group 1: Appointments - Zhu Zhaoyun, an academician of the Chinese Academy of Engineering, has previously served as the director of the Yunnan Provincial Institute of Drug Research and the R&D director of Yunnan Baiyao Group [1] - Zhang Ning, a professor at Peking University, has held positions such as the deputy director of the Peking University Health Science Center and the vice president of Tianjin Medical University [1] Group 2: Strategic Goals - The company aims to leverage both "traditional Chinese medicine" and "innovative drugs" to drive growth and development [1] - The appointments are part of a broader strategy to deepen the integration of traditional Chinese medicine with modern scientific advancements [1]

Core Viewpoint - China Resources Pharmaceutical announced the potential sale of approximately 17.87% equity in Tianmai Biotechnology, with a listing price of around RMB 1.42 billion, marking its exit from being a core shareholder after a 10-year investment [1][4]. Group 1: Company Overview - Tianmai Biotechnology, established in 2010, focuses on the development of diabetes-related products and services [1]. - The company has a diverse shareholder structure with 21 shareholders, where China Resources Pharmaceutical Investment holds a 20% stake, making it the largest and core shareholder [1]. Group 2: Investment History - China Resources Pharmaceutical initially invested in Tianmai Biotechnology due to its focus on the significant diabetes market and the potential of oral insulin ORM-D-0801 [3]. - The investment history includes a previous sale of 14.12% equity for approximately HKD 1.147 billion in 2017, triggered by Tianmai's failure to obtain GMP certification [3][4]. Group 3: Product Development - Tianmai Biotechnology has partnered with Singapore's Vanier Company for joint research and development of biopharmaceuticals, establishing bases in Israel and China [2]. - The company developed ORM-D-0801, an oral insulin product aimed at treating type 2 diabetes, which faced challenges in clinical trials [6]. Group 4: Market Challenges - The oral insulin ORM-D-0801 failed to meet primary and secondary endpoints in a Phase III trial, leading to its rejection by the National Medical Products Administration in December 2025 [7]. - Following the failure of ORM-D-0801, Tianmai Biotechnology must return to the traditional insulin market, facing competition from established players without the scale or technology reserves [7]. Group 5: Strategic Decisions - The decision to sell Tianmai Biotechnology's stake reflects China Resources Pharmaceutical's broader strategy of divesting non-core assets amid changing market conditions [8]. - This strategic move indicates a proactive approach to risk management and resource allocation in a complex market environment [8].

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Chaohui Pharmaceutical Co., Ltd., has received acceptance for the drug registration application of Benzocaine Gel by the National Medical Products Administration, indicating progress in the company's product pipeline [1] Group 1: Product Development - The drug is a self-developed chemical product intended for topical anesthesia, suitable for adults and infants over one month old [1] - The cumulative R&D investment for this drug is approximately RMB 7.19 million (unaudited) as of December 2025 [1] Group 2: Market Potential - According to IQVIA CHPA, the sales revenue of Benzocaine Gel in mainland China (excluding Hong Kong, Macau, and Taiwan) is projected to be around RMB 443 million in 2024 [1]

格隆汇2月10日丨恒瑞医药(600276.SH)公布，公司子公司苏州盛迪亚生物医药有限公司收到国家药品监 督管理局下发的《受理通知书》，公司注射用瑞康曲妥珠单抗的药品上市许可申请获受理，且已被纳入 优先审评程序。 公司注射用瑞康曲妥珠单抗已于2025年5月在国内获批上市，适用于治疗存在HER2（ERBB2）激活突 变且既往接受过至少一种系统治疗的不可切除的局部晚期或转移性非小细胞肺癌（NSCLC）成人患 者。 ...

阿斯利康今年预计还将公布超过20项三期试验结果，且还有100多项三期临床试验正在进行中，包括多种创新技术疗法。 2月10日，阿斯利康公布2025年第四季度及全年财报。2025年，阿斯利康全球总营收达587.39亿美元，同比增长8%，其中阿斯利康中国 2025年总营收达66.54亿美元，同比增长4%，占总收入比约11%，生物制药、肿瘤、罕见病三大业务领域均实现增长。 阿斯利康预测，2026年利润和销售将继续增长，这主要得益于癌症治疗和新药的需求。去年第四季度，阿斯利康肿瘤药业务增长20% 至70.3亿美元，但心血管业务受仿制药竞争影响下跌6%至30.5亿美元。 阿斯利康近期还调整了上市架构，普通股于2月2日在纽约证券交易所开始交易。 阿斯利康的目标是到2030年，年度销售额达到800亿美元，这一目标的实现将通过开发新药物和进行投资来实现。公司计划到2030年推 出20款全球创新药。 为此，阿斯利康正在推动在美国和中国的扩张。上个月，阿斯利康宣布从现在到2030年将在中国投资超1000亿元人民币，以扩大在药 品生产与研发领域的布局。这也是阿斯利康史上最大规模对华投资计划。 过去几年来，阿斯利康不断加大与中国领先生 ...

Core Viewpoint - The company, China Resources Double Crane (华润双鹤), is participating in a national procurement process for pharmaceutical products, with some of its drugs expected to be selected in the upcoming procurement results, which will be implemented by the end of March 2026 [1][2] Group 1: Company Performance - In the first three quarters of 2025, the sales revenue of Valsartan and Hydrochlorothiazide tablets was 426 million yuan, accounting for 5.14% of the total revenue [1] - The sales revenue of Nifedipine Controlled-Release Tablets was 138 million yuan, representing 1.67% of the total revenue [1] - The sales revenue of Enoxaparin Sodium Injection was 119 million yuan, making up 1.43% of the total revenue [1] - The sales revenue of Nifedipine Sustained-Release Tablets (II) was 108 million yuan, accounting for 1.30% of the total revenue [1] - The sales revenue of Irbesartan Dispersible Tablets was 79 million yuan, which is 0.95% of the total revenue [1] Group 2: Industry Context - The upcoming procurement process aims to maintain stable or decreasing prices, providing medical institutions with greater choice among selected suppliers, which helps ensure continuity in clinical medication and reduces the risk of medication switching due to centralized procurement [2] - Although the selection may lead to a decrease in overall sales revenue, it is expected to solidify the company's existing market share, with potential for increased market penetration due to brand influence and reliable supply capabilities [2]

Core Viewpoint - China Resources Double Crane announced that the company and some subsidiaries participated in the national organized procurement for drugs whose agreements are expiring, with several drugs expected to be selected for procurement [1] Group 1: Selected Drugs and Revenue Impact - The main drugs expected to be selected include: - Valsartan and Hydrochlorothiazide Tablets with projected sales revenue of 517 million yuan, accounting for 4.61% of the 2024 annual revenue [1] - Nifedipine Controlled-Release Tablets with projected sales revenue of 147 million yuan, accounting for 1.31% of the 2024 annual revenue [1] - Enoxaparin Sodium Injection with projected sales revenue of 128 million yuan, accounting for 1.14% of the 2024 annual revenue [1] - Nifedipine Sustained-Release Tablets (II) with projected sales revenue of 118 million yuan, accounting for 1.05% of the 2024 annual revenue [1] - Irbesartan Dispersible Tablets with projected sales revenue of 110 million yuan, accounting for 0.98% of the 2024 annual revenue [1]

| AZN 阿斯利康 | | | | --- | --- | --- | | 188 010 L -5.020 -2.60% | | 收盘价 02/09 16:00 美东 | | 192.200↑ 4.190 +2.23% | | 盘前价 02/10 04:05 美东 | | 三 24 S m 9 目 ♥ 自选 | | ● 快捷交易 | | 最高价 192.760 | 开盘价 191.800 | 成交量 303.08万 | | 最低价 187.060 | 昨收价 193.030 | 成交额 5.74亿 | | 平均价 189.232 | 市盈率 IM 31.23 | 总市值 2915.93亿(…) | | 振 幅 2.95% | 市密率(静) 41.78 | 总股本 15.51亿 | | 换手率 0.20% | 市净率 6.354 | 流通值 2902.05亿 | | 52周景高 193.970 | 委 比 -- | 流通股 15.44亿 | | 52周最低 121.634 | 量 比 0.93 | 色 手 1股 | | 历史最高 193.970 | 股息TTM 3.133 | | | 历史最低 10.525 ...

Core Insights - AstraZeneca reported a core earnings per share of $2.12 for Q4, with total revenue increasing by 2% to $15.5 billion, aligning with consensus expectations of $2.12 billion and $15.4 billion [1] - The company forecasts steady profit growth by 2026, with sales growth expected to slow down, focusing on the demand for its cancer drugs while increasing R&D investments and addressing geopolitical pressures and patent expirations [1] - AstraZeneca aims for total revenue growth in the mid-single digits and core profit growth in the low double digits by 2026, despite the impact of a major diabetes drug's patent expiration [1] Revenue Breakdown - Q4 cancer drug sales rose by 20% to $7.03 billion, while cardiovascular drug revenue fell by 6% to $3.05 billion, partly due to competition from generics, including diabetes and heart failure drug Farxiga [1] - The company is on track to achieve its ambitious goal of $80 billion in annual sales by 2030 under the leadership of CEO Pascal Soriot, driven by new drugs and investments despite unstable U.S. tariffs and healthcare policies [1] Future Plans - AstraZeneca reiterated its goal of achieving $80 billion in revenue by the end of the decade and plans to announce results from up to 20 advanced clinical trials this year [4] - Upcoming new drugs will target obesity, lung cancer, and chronic obstructive pulmonary disease [4] - The company plans to increase its annual dividend by approximately 3% to $3.30, reflecting confidence in its long-term plans [4] Market Strategies - AstraZeneca has taken significant steps to achieve growth in the U.S. and China, including a $50 billion manufacturing agreement in the U.S. and a $15 billion investment in China [4] - The experimental obesity drug, elecoglipron, is entering the final stages of clinical trials [4] - Despite potential impacts from U.S. drug pricing agreements, the company believes it can withstand the effects of these transactions [4]